191 related articles for article (PubMed ID: 18182343)
61. Histone deacetylases as new therapy targets for platinum-resistant epithelial ovarian cancer.
Pchejetski D; Alfraidi A; Sacco K; Alshaker H; Muhammad A; Monzon L
J Cancer Res Clin Oncol; 2016 Aug; 142(8):1659-71. PubMed ID: 26560874
[TBL] [Abstract][Full Text] [Related]
62. Recurrent epithelial ovarian cancer: pharmacotherapy and novel therapeutics.
Modesitt SC; Jazaeri AA
Expert Opin Pharmacother; 2007 Oct; 8(14):2293-305. PubMed ID: 17927484
[TBL] [Abstract][Full Text] [Related]
63. Symptom control in patients with recurrent ovarian cancer: measuring the benefit of palliative chemotherapy in women with platinum refractory/resistant ovarian cancer.
Friedlander M; Butow P; Stockler M; Gainford C; Martyn J; Oza A; Donovan HS; Miller B; King M
Int J Gynecol Cancer; 2009 Dec; 19 Suppl 2():S44-8. PubMed ID: 19955914
[TBL] [Abstract][Full Text] [Related]
64. Epidemiology and treatment patterns of epithelial ovarian cancer.
Jessmon P; Boulanger T; Zhou W; Patwardhan P
Expert Rev Anticancer Ther; 2017 May; 17(5):427-437. PubMed ID: 28277806
[TBL] [Abstract][Full Text] [Related]
65. Update of randomized trials in recurrent disease.
Pujade-Lauraine E; Alexandre J
Ann Oncol; 2011 Dec; 22 Suppl 8():viii61-viii64. PubMed ID: 22180404
[TBL] [Abstract][Full Text] [Related]
66. Advances in epithelial ovarian cancer therapy.
Kroep JR
Curr Pharm Des; 2012; 18(25):3735-40. PubMed ID: 22591426
[TBL] [Abstract][Full Text] [Related]
67. Potential application of curcumin and its analogues in the treatment strategy of patients with primary epithelial ovarian cancer.
Terlikowska KM; Witkowska AM; Zujko ME; Dobrzycka B; Terlikowski SJ
Int J Mol Sci; 2014 Nov; 15(12):21703-22. PubMed ID: 25429431
[TBL] [Abstract][Full Text] [Related]
68. First-line randomized trials: revisiting the Ptolemaic universe.
Bookman MA
Int J Gynecol Cancer; 2008; 18 Suppl 1():47-52. PubMed ID: 18336401
[TBL] [Abstract][Full Text] [Related]
69. Oral altretamine used as salvage therapy in recurrent ovarian cancer.
Chan JK; Loizzi V; Manetta A; Berman ML
Gynecol Oncol; 2004 Jan; 92(1):368-71. PubMed ID: 14751188
[TBL] [Abstract][Full Text] [Related]
70. Characterization of disease progression in ovarian cancer by utilizing 'chemograms' of ovarian cancer stem cells.
Guddati AK; Shaheen S
J Chemother; 2013 Jun; 25(3):184-91. PubMed ID: 23783145
[TBL] [Abstract][Full Text] [Related]
71. Leuprolide acetate as a salvage-therapy in relapsed epithelial ovarian cancer.
Marinaccio M; D'Addario V; Serratì A; Pinto V; Cagnazzo G
Eur J Gynaecol Oncol; 1996; 17(4):286-8. PubMed ID: 8856307
[TBL] [Abstract][Full Text] [Related]
72. Antibody-drug conjugates for the treatment of ovarian cancer.
Calo CA; O'Malley DM
Expert Opin Biol Ther; 2021 Jul; 21(7):875-887. PubMed ID: 32463296
[TBL] [Abstract][Full Text] [Related]
73. Epithelial ovarian cancer: a review of current management.
Guppy AE; Nathan PD; Rustin GJ
Clin Oncol (R Coll Radiol); 2005 Sep; 17(6):399-411. PubMed ID: 16149282
[TBL] [Abstract][Full Text] [Related]
74. Salvage therapy for recurrent epithelial ovarian cancer.
Baker VV
Hematol Oncol Clin North Am; 2003 Aug; 17(4):977-88. PubMed ID: 12959187
[TBL] [Abstract][Full Text] [Related]
75. Maintenance treatment of recurrent ovarian cancer: Is it ready for prime time?
DiSilvestro P; Alvarez Secord A
Cancer Treat Rev; 2018 Sep; 69():53-65. PubMed ID: 29908480
[TBL] [Abstract][Full Text] [Related]
76. Recurrent ovarian cancer.
Pujade-Lauraine E; Combe P
Ann Oncol; 2016 Apr; 27 Suppl 1():i63-i65. PubMed ID: 27141075
[TBL] [Abstract][Full Text] [Related]
77. [Treatment of recurrent ovarian cancer].
Robová H; Rob L; Pluta M; Halaska M; Chmel R
Ceska Gynekol; 2009 Dec; 74(6):464-8. PubMed ID: 21246797
[TBL] [Abstract][Full Text] [Related]
78. Benefits of enhancing the platinum-free interval in the treatment of relapsed ovarian cancer: more than just a hypothesis?
Ledermann JA
Int J Gynecol Cancer; 2011 May; 21 Suppl 1():S9-11. PubMed ID: 21540669
[TBL] [Abstract][Full Text] [Related]
79. [Not Available].
Floquet A; Berton-Rigaud D; Ferron G; Freyer G; Hardy-Bessard AC; You B
Bull Cancer; 2017 May; 104 Suppl 1():S24-S31. PubMed ID: 28625312
[TBL] [Abstract][Full Text] [Related]
80. The importance of dose and schedule in cancer chemotherapy: epithelial ovarian cancer.
Mainwaring PN; Gore ME
Anticancer Drugs; 1995 Oct; 6 Suppl 5():29-41. PubMed ID: 8845493
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
